Andreas Plückthun

☆ Save On Wikipedia ↗
Andreas Plückthun
Born(1956-05-07)May 7, 1956
Heidelberg, Germany
CitizenshipGerman, Swiss
Alma materUniv. of Heidelberg; Univ. of California, San Diego (PhD, 1982)
Known forDARPins; ribosome display; antibody engineering, antibody expression in E. coli; synthetic antibody libraries; GPCR stabilization
AwardsChristian B. Anfinsen Award (2016); Wilhelm-Exner Medal (2002); Karl-Heinz Beckurts Prize (2000)
Scientific career
FieldsBiochemistry; protein engineering; directed evolution
InstitutionsUniversity of Zurich (1993–present); Max Planck Institute for Biochemistry (1985–1993)
Thesis (1982)
Edward A. Dennis (1978–1982)

Andreas Plückthun (born May 7, 1956) is a German–Swiss biochemist and protein engineer, known for foundational contributions to antibody engineering, directed evolution technologies, and the development of alternative binding proteins. He has been a full professor of biochemistry at the University of Zurich since 1993[1] and is widely recognized for pioneering work that has influenced both academic research and the biotechnology industry.

His research has played a central role in establishing modern protein engineering as a discipline, particularly through the development of synthetic antibody libraries, ribosome display, and Designed Ankyrin Repeat Proteins (DARPins), which have been translated into clinical and industrial applications.[2]

Early Life and Education

Plückthun studied chemistry at Heidelberg University before pursuing graduate studies at the University of California, San Diego, where he obtained a Ph.D. in 1982 under Edward Dennis. His doctoral work focused on enzymatic catalysis at interfaces.[1]

He subsequently conducted postdoctoral research at Harvard University (1982–1985) with Jeremy Knowles, working on protein transport through the membrane in bacteria.[1]

Academic Career

From 1985 to 1993, Plückthun held research leadership positions in Germany, including group leader roles at the Gene Center Munich and the Max Planck Institute of Biochemistry. In 1993, he was appointed full professor of biochemistry at the University of Zurich, where he has led a research program focused on protein engineering, design, and evolution.[1][2]

Over his career, he has trained a large number of scientists, including more than 120 doctoral students and dozens of postdoctoral researchers, many of whom have gone on to academic and industry leadership roles.[3]

Research Contributions

Antibody Engineering and Synthetic Libraries

Plückthun's early work demonstrated the expression of functional antibody fragments in Escherichia coli, thereby overcoming a major technical barrier in recombinant antibody production.[4][5][6] This work enabled the development of modern antibody engineering techniques and laid the groundwork for the first fully synthetic antibody libraries.

These libraries, including modular combinatorial systems, allowed rapid generation of antibodies without immunization and have since become widely used in both research and therapeutic development. Several antibodies derived from such technologies have been translated into clinical applications.[6][7]

Designed Ankyrin Repeat Proteins (DARPins)

Building on insights from antibody stability and folding, Plückthun developed Designed Ankyrin Repeat Proteins (DARPins), a class of engineered binding proteins designed to overcome limitations of conventional antibodies.[8][9]

DARPins exhibit high stability, strong binding affinity, and efficient expression across multiple systems. They have been developed into therapeutic candidates and research tools, including applications targeting intracellular proteins and complex biological pathways.[10][9]

Ribosome Display and Directed Evolution

Plückthun introduced ribosome display, a cell-free system for protein evolution that allows the selection of high-affinity binders from extremely large libraries. As it can directly incorporate mutagenesis by e.g. error-prone PCR, it can truly evolve a protein sequence. This method expanded the scale and efficiency of directed evolution beyond cell-based approaches.[11][12]

Using ribosome display, proteins have been evolved to achieve very high binding affinities, and specialized variants of the method have been developed to improve protein stability and folding efficiency. These technologies have become widely adopted tools in protein engineering and biotechnology.[12]

Engineering of Membrane Proteins and GPCRs

His group developed methods to evolve and stabilize G protein-coupled receptors (GPCRs), a class of membrane proteins that are central drug targets but difficult to study structurally.[13][14]

By combining directed evolution with high-throughput selection techniques, these methods enabled improved expression, stability, and structural analysis of GPCRs using crystallography, cryo-electron microscopy, and other approaches, as well as enabling the direct high-throughput screening for binding of ligands.[15][16][14]

Gene Delivery and Synthetic Virus-like Particles

More recently, Plückthun's research has focused on precision gene delivery systems based on engineered virus-like particles derived from adenoviruses. These systems are designed to selectively target specific cell types based on their surface receptors, while avoiding immune detection.[1][17][18]

Applications demonstrated in preclinical models include targeted delivery to tumor cells and immune cells, enabling localized therapeutic expression of antibodies and cytokines.[1]

Entrepreneurial and Industrial Contributions

Plückthun has played a key role in translating academic research into biotechnology ventures:

  • Co-founder of MorphoSys AG (1992), based on antibody engineering technologies, later acquired by Novartis[19]
  • Co-founder of Molecular Partners AG (2004), developing DARPin-based therapeutics[9]
  • Co-founder of G7 Therapeutics, focused on GPCR-targeted drug discovery (later integrated into Nxera Pharma)[20]

These companies have contributed to the development of therapeutic candidates and commercial platforms in biotechnology.

Awards and Honors

Plückthun has received numerous international awards recognizing his contributions to protein science and biotechnology, including:

  • Christian B. Anfinsen Award of the Protein Society (2016)[21]
  • European Research Council (ERC) Senior Investigator Grant (2011)[22]
  • ERC Synergy Grant (2018)[23]
  • Wilhelm-Exner Medal (2002)[24]
  • Grand Prix Européen d'Innovation (2002)[25]
  • J.P. Morgan Chase Health Award (2002)[19]
  • Karl-Heinz Beckurts Prize (2000)[26]
  • Young Investigator Award of the German Chemical Industry (1990)[27]

He has also been elected to major scientific organizations, including:

Scientific Output and Impact

Plückthun has authored more than 550 scientific publications, with over 60,000 citations and an h-index exceeding 130, reflecting sustained influence across multiple areas of protein science.[30][3]

His work spans fundamental biochemical research, methodological innovation, and translational applications, contributing to advances in therapeutic antibody development, protein design, and targeted gene delivery.[2]

Legacy and Influence

Plückthun is regarded as a key figure in the development of modern protein engineering. His contributions have enabled technologies that are widely used in both academic research and the biotechnology industry, bridging the gap between fundamental science and clinical application.[31][32]

His work continues to influence fields including antibody therapeutics, structural biology, and synthetic biology, with ongoing research expanding into targeted gene delivery and precision medicine approaches as well as new approaches to design binding molecules.[2][1]

References

  1. "Andreas Plückthun — Lab profile". Plückthun Lab, University of Zurich.
  2. "Research — The Plückthun Lab". University of Zurich.
  3. "Andreas Plückthun — lab profile and publication metrics". University of Zurich Department of Biochemistry.
  4. Skerra, A.; Plückthun, A. (1988). "Assembly of a functional immunoglobulin Fv fragment in Escherichia coli". Science. 240 (4855): 1038–1041. doi:10.1126/science.3285470.
  5. Plückthun, A. (1991). "Antibody engineering: advances from the use of Escherichia coli expression systems". Bio/Technology. 9: 545–551.
  6. Plückthun, A. (1990). "Antibodies from Escherichia coli". Nature. 347: 497–498.
  7. Plückthun, A.; Moroney, S. E. (2005). "Modern antibody technology: The impact on drug development". In Knäblein, J. (ed.). Modern Biopharmaceuticals. Vol. 3. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA. pp. 1147–1186.
  8. Tamaskovic, R.; Simon, M.; Stefan, N.; Schwill, M.; Plückthun, A. (2012). "Designed ankyrin repeat proteins (DARPins): from research to therapy". Methods in Enzymology. 503: 101–134. doi:10.1016/B978-0-12-396962-0.00005-7.
  9. Plückthun, A. (2015). "Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy". Annual Review of Pharmacology and Toxicology. 55: 489–511. doi:10.1146/annurev-pharmtox-010611-134654.
  10. Walser, M.; Mayor, J.; Rothenberger, S. (2022). "Designed Ankyrin Repeat Proteins: A New Class of Viral Entry Inhibitors". Viruses. 14 (10): 2242.
  11. Hanes, J.; Plückthun, A. (1997). "In vitro selection and evolution of functional proteins by using ribosome display". Proceedings of the National Academy of Sciences USA. 94 (10): 4937–4942. doi:10.1073/pnas.94.10.4937. PMC 24609.
  12. Zahnd, C.; Amstutz, P.; Plückthun, A. (2007). "Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target". Nature Methods. 4: 269–279. doi:10.1038/nmeth1003.
  13. Sarkar, C. A.; Dodevski, I.; Kenig, M.; Dudli, S.; Mohr, A.; Hermans, E.; Plückthun, A. (2008). "Directed evolution of a G protein-coupled receptor for expression, stability, and binding selectivity". Proc. Natl. Acad. Sci. U. S. A. 105: 14808–14813.
  14. Schöppe, J.; Ehrenmann, J.; Waltenspühl, Y.; Plückthun, A. (2022). "Universal platform for the generation of thermostabilized GPCRs that crystallize in LCP". Nature Protocols. 17: 698–726.
  15. Milic, D.; Veprintsev, D.B. (2015). "Large-scale production and protein engineering of G protein-coupled receptors for structural studies". Front Pharmacol. 6: 66.
  16. Klenk, C.; Ehrenmann, J.; Schütz, M.; Plückthun, A. (2016). "A generic selection system for improved expression and thermostability of G protein-coupled receptors by directed evolution". Scientific Reports. 6 21294. doi:10.1038/srep21294. PMC 4758055.
  17. Schmid, M.; Ernst, P.; Honegger, A.; Suomalainen, M.; Zimmermann, M.; Braun, L.; Stauffer, S.; Thom, C.; Dreier, B.; Eibauer, M.; Kipar, A.; Vogel, V.; Greber, U. F.; Medalia, O.; Plückthun, A. (2018). "Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control". Nature Communications. 9: 450.
  18. Dreier, B.; Honegger, A.; Hess, C.; Nagy-Davidescu, G.; Mittl, P. R.; Grütter, M. G.; Belousova, N.; Mikheeva, G.; Krasnykh, V.; Plückthun, A. (2013). "Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters". Proc. Natl. Acad. Sci. U. S. A. 110: E869–877.
  19. "MorphoSys Co-Founder Receives Award for Outstanding Scientific Achievements". ChemEurope. December 2000.
  20. Scott, D.J. "The Florey Institute researcher profile".
  21. "Christian B. Anfinsen Award — Andreas Plückthun". PubMed Central.
  22. "ERC 2010 Advanced Grants results — all domains" (PDF). European Research Council.
  23. "ERC Synergy Grant". University of Zurich.
  24. "Andreas Plückthun — Wilhelm Exner Medal". Wilhelm Exner Foundation.
  25. "Andreas Plückthun, PhD". Informa Connect — Antibody Engineering & Therapeutics Speaker Profile.
  26. "Karl-Heinz Beckurts Prize 2000". Karl-Heinz Beckurts Foundation.
  27. "Dozentenpreis des Fonds der Chemischen Industrie" (PDF). Verband der Chemischen Industrie.
  28. "Andreas Plückthun — EMBO member profile". European Molecular Biology Organization.
  29. "Andreas Plückthun — member entry". German Academy of Sciences Leopoldina.
  30. "Andreas Plückthun". Academia.edu / University of Zurich profile.
  31. "Andreas Plückthun, PhD". The Antibody Society.
  32. "Andreas Plückthun". EPFL CH635 lecture profile.